Stem Cell Therapeutics Advances CD47 Antagonist Program Into IND-Enabling Phase

Stem Cell Therapeutics Corp. (TSX VENTURE:SSS)(OTCQX:SCTPF), a biopharmaceutical
company developing cancer stem cell- related therapeutics, today announced that
it has advanced its CD47 antagonist program into an Investigational New Drug
(IND) enabling phase. In collaboration with a contract manufacturing
organization, Stem Cell Therapeutics (SCT) will begin the manufacturing process
to generate drug for formal toxicology studies and a subsequent phase I clinical
study, which is anticipated to begin in H2/2015.


SCT's program targets the activity of CD47, a molecule upregulated on many
leukemias and solid tumors. CD47 delivers a "do not eat" signal that suppresses
macrophage phagocytosis, allowing cancer cells, including cancer stem cells, to
escape immune-mediated destruction. SCT has chosen to block the CD47 protein
using a modified version of its natural ligand, SIRPalpha, fused to an
immunoglobulin Fc region. The SIRPaFc fusion protein has shown excellent
anti-leukemic activity both in vitro and in human xenograft models, and exhibits
a unique binding profile compared to other CD47 blocking agents. These results,
as well as encouraging safety data emerging from a recently completed non-human
primate study, will be reported at a future scientific conference.


"We believe that SIRPaFc, through its ability to activate the innate immune
response and eliminate cancer stem cells, holds great promise as a novel
immunotherapy," commented Dr. Niclas Stiernholm. "The transition from the
research to the IND-enabling phase is a key milestone for the SIRPalphaFc
program, and we will continue on the path towards clinical testing."


About Cancer Stem Cells:

The cancer stem cell (CSC) concept postulates that the growth of tumors is
driven by a rare population of dedicated cells that have stem cell-like
properties, including self-renewal. While the bulk of a tumor consists of
rapidly proliferating cells and differentiated cells, neither of which is
capable of self-renewal, a small population of CSCs provides for long-term
maintenance of the cancer. Although the CSC concept was first postulated in the
1960s, it wasn't until 1994 that proof of their existence was demonstrated, when
Dr. John Dick and colleagues in Toronto isolated CSCs (known as leukemic stem
cells, or LSCs) from bulk acute myeloid leukemia cells. More recently, CSCs have
been identified in many other human malignancies, including solid tumors such as
bladder, brain, breast, colon, ovarian and prostate cancers. There is
accumulating evidence that CSCs are resistant to conventional chemotherapies and
radiation. Thus, CSCs are thought to be responsible for a phenomenon well known
to oncologists: most patients will experience an initial response to
conventional chemotherapies but will ultimately relapse. To cure cancer CSCs
need to be destroyed, but the current armament of therapies is poorly equipped
to do so.


About Stem Cell Therapeutics:

Stem Cell Therapeutics Corp. (SCT) is a biopharmaceutical company dedicated to
advancing cancer stem cell discoveries into novel and innovative cancer
therapies. Building on over half a century of leading and groundbreaking
Canadian stem cell research, the company is supported by established links to a
group of Toronto academic research institutes and cancer treatment centers,
representing one of the world's most acclaimed cancer research hubs. The Company
has two premier preclinical programs, SIRPaFc and a CD200 monoclonal antibody
(mAb), which target two key immunoregulatory pathways that tumor cells exploit
to evade the host immune system. SIRPaFc is an antibody-like fusion protein that
blocks the activity of CD47, a molecule that is upregulated on cancer stem cells
in AML and several other tumors. The CD200 mAb is a fully human monoclonal
antibody that blocks the activity of CD200, an immunosuppressive molecule that
is overexpressed by many hematopoietic and solid tumors. SCT's clinical stage
programs include the recently in-licensed program focused on the structure of
tigecycline, which is currently being evaluated in a multi-centre Phase I study
in patients with acute myeloid leukemia (AML), as well as TTI-1612, a non-cancer
stem cell asset that recently completed a 28-patient Phase I trial in
interstitial cystitis ("IC") patients. For more information, visit:
www.stemcellthera.com.


Caution Regarding Forward-Looking Information:

This press release may contain forward-looking statements, which reflect SCT's
current expectation regarding future events. These forward-looking statements
involve risks and uncertainties that may cause actual results, events or
developments to be materially different from any future results, events or
developments expressed or implied by such forward-looking statements. Such
factors include changing market conditions; the successful and timely completion
of pre-clinical and clinical studies; the establishment of corporate alliances;
the impact of competitive products and pricing; new product development risks;
uncertainties related to the regulatory approval process or the ability to
obtain drug product in sufficient quantity or at standards acceptable to health
regulatory authorities to complete clinical trials or to meet commercial demand;
and other risks detailed from time to time in SCT's ongoing quarterly and annual
reporting. Except as required by applicable securities laws, SCT undertakes no
obligation to publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Stem Cell Therapeutics Corp.
James Parsons
Chief Financial Officer
[phone]
[e-mail]
www.stemcellthera.com


ProActive Capital
Jeff Ramson
Investor Contact
[phone]
[e-mail]


ProActive Capital
Kirin Smith
Investor Contact
[phone]
[e-mail]